scholarly journals Clinical Remission of Chronic Spontaneous Urticaria (CSU): A Targeted Literature Review

2021 ◽  
Author(s):  
Maria-Magdalena Balp ◽  
Anna C. Halliday ◽  
Thomas Severin ◽  
Saoirse A. Leonard ◽  
Gautam Partha ◽  
...  
Keyword(s):  
Literature Review ◽  
Clinical Remission ◽  
Chronic Spontaneous Urticaria

scholarly journals Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience

2016 ◽  
Vol 1 ◽  
pp. 64-70 ◽  
Author(s):  
Joanna Dawicka ◽  
Aleksandra Wilkowska ◽  
Elżbieta Grubska-Suchanek ◽  
Roman Nowicki
Keyword(s):  
Literature Review ◽  
Chronic Spontaneous Urticaria

Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review

2010 ◽  
Vol 29 (6) ◽  
pp. 629-635 ◽  
Author(s):  
Mónica Bogas ◽  
Pedro Machado ◽  
Ana Filipa Mourão ◽  
Lúcia Costa ◽  
Maria José Santos ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Clinical Remission ◽  
Methotrexate Treatment ◽  
Common Infection

scholarly journals Adding Water to the Mill: Olmesartan-Induced Collagenous Sprue—A Case Report and Brief Literature Review

2016 ◽  
Vol 2016 ◽  
pp. 1-2 ◽  
Author(s):  
Claudine Desruisseaux ◽  
Michaël Bensoussan ◽  
Etienne Désilets ◽  
Hanh-Khiem Tran ◽  
Robert Arcand ◽  
...  
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Clinical Remission ◽  
Poor Prognosis ◽  
Significant Proportion ◽  
Rare Condition ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Unique Case

Collagenous sprue (CS) is a distinct clinicopathological disorder histologically defined by a thickened subepithelial band (Freeman, 2011). It is a rare condition which has been recently observed in a significant proportion of sprue-like enteropathy associated with olmesartan, a novel entity described by Rubio-Tapia et al. in 2012. CS is historically associated with a poor prognosis (Marthey et al., 2014). However, histological and clinical improvements have been described in most studies with concomitant usage of corticosteroids and/or gluten-free diet (Marthey et al., 2014). We report a unique case of olmesartan-induced collagenous sprue in a 79-year-old man that showed complete histological and clinical remission with the sole withdrawal of the incriminating drug. The literature on this topic is briefly reviewed.

scholarly journals Chronic spontaneous urticaria: news about problem and treatment (literature review)

2019 ◽  
Vol 2 (26) ◽  
pp. 15-20
Author(s):  
L. S. Kruglova
Keyword(s):  
Partial Response ◽  
Literature Review ◽  
Effective Dose ◽  
Chronic Urticaria ◽  
Large Percentage ◽  
Chronic Spontaneous Urticaria ◽  
H1 Receptor ◽  
Treatment Results ◽  
Receptor Blockers ◽  
Mechanisms Of Development

Despite advances in understanding the mechanisms of development of chronic urticaria, in a large percentage of cases there are unsatisfied treatment results, there is no possibility of controlling the disease. Currently, the treatment of patients with chronic urticaria is of a staged nature. In 2014, omalizumab was registered in Russia for extended indications, which makes it possible to achieve control of the refractory form of chronic spontaneous urticaria. The article presents data on the effectiveness and safety of omalizumab. According to the results of numerous studies, omalizumab showed a quick and pronounced effect in the treatment of patients with chronic spontaneous urticaria who do not respond to therapy with H1-receptor blockers. The issues of effective dose, safety and tolerability of the therapy, timing of evaluating the effectiveness, duration of the course and tactics of managing patients with a partial response or lack of response were considered.

scholarly journals IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review

2022 ◽  
Vol 14 (1) ◽  
pp. 131
Author(s):  
Liming Zhang ◽  
Li Qiu ◽  
Jian Wu ◽  
Yumeng Qi ◽  
Hexiao Wang ◽  
...  
Keyword(s):  
Literature Review ◽  
Chronic Spontaneous Urticaria ◽  
Chinese Patients ◽  
Thyroid Autoantibodies

scholarly journals DOP69 Ozanimod for induction treatment of Moderate-to-Severe Ulcerative Colitis: Results from a systematic literature review and network meta-analyses

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S103-S105
Author(s):  
K Eaton ◽  
C Duperrouzel ◽  
P Bhandari ◽  
S Craigie ◽  
A Bonner ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Literature Review ◽  
Clinical Response ◽  
Systematic Literature Review ◽  
Clinical Remission ◽  
Similar Efficacy ◽  
Induction Treatment ◽  
Induction Phase ◽  
Severe Ulcerative Colitis ◽  
Meta Analyses

Abstract Background Ozanimod (OZA) is an orally administered, selective sphingosine-1-phosphate receptor modulator that has been evaluated versus placebo (PBO) in the phase 3 True North trial in the treatment of adult patients with moderate-to-severe ulcerative colitis (UC). The objective of this study was to compare the relative efficacy of OZA versus other approved moderate-to-severe UC therapies via network meta-analyses (NMA). Methods A systematic literature review was conducted to identify randomised clinical trials published from Jan 1, 2000 to Oct 21, 2020 that evaluated biological therapies (infliximab [IFX], adalimumab [ADA], golimumab [GOL], vedolizumab [VEDO], and ustekinumab [UST]) or an oral small molecule (tofacitinib [TOF]) for adults with moderate-to-severe UC. Bayesian NMAs were performed to determine the comparative efficacy of these therapies based on clinical remission, clinical response, and endoscopic improvement in the induction phase (6 to 14 weeks). Three populations were considered: all patients (overall), first-line (biologic-naïve), or those with exposure to or failure of prior biologic therapy (biologic-experienced). All six comparator therapies were included in the overall and biologic-naive populations, whereas the biologic-experienced population included ADA, VEDO, UST, and TOF due to lack of biologic-experienced data for IFX and GOL. Results Twenty-two RCTs examining 10,269 patients in the induction phase were included (Figure 1). All therapies offered significant improvement over PBO across networks apart from ADA in the analysis of clinical remission and clinical response in the biologic-experienced population and ADA, VEDO, and OZA in the analysis of endoscopic improvement in the biologic-experienced population. In the overall and biologic-naïve populations, OZA offered similar efficacy to all other therapies across endpoints except for a significant improvement in endoscopic improvement over ADA (overall: OR 2.01, 95% CrI 1.14, 3.66 [Figure 2]; biologic-naïve: OR 2.13, 95% CrI 1.02, 4.50 [Figure 3]). OZA also offered similar efficacy to all other therapies across endpoints in the biologic-experienced population except for an improvement in clinical remission (OR 4.16, 95% CrI 1.55, 11.24) and clinical response (OR 3.11, 95% CrI 1.40, 7.08) over ADA (Figure 4). Conclusion This NMA suggests that OZA provides similar induction efficacy on clinical remission, clinical response, and endoscopic improvement versus other approved moderate-to-severe UC therapies regardless of prior biologic treatment status.

Sign in / Sign up

Export Citation Format

Share Document